Theravance Biopharma (TBPH) Competitors $8.63 -0.10 (-1.15%) Closing price 04:00 PM EasternExtended Trading$8.64 +0.00 (+0.06%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. HRMY, DVAX, GLPG, CNTA, AGIO, KNSA, ANIP, JANX, MNKD, and ARWRShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Harmony Biosciences (HRMY), Dynavax Technologies (DVAX), Galapagos (GLPG), Centessa Pharmaceuticals (CNTA), Agios Pharmaceuticals (AGIO), Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), MannKind (MNKD), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical preparations" industry. Theravance Biopharma vs. Harmony Biosciences Dynavax Technologies Galapagos Centessa Pharmaceuticals Agios Pharmaceuticals Kiniksa Pharmaceuticals ANI Pharmaceuticals Janux Therapeutics MannKind Arrowhead Pharmaceuticals Theravance Biopharma (NASDAQ:TBPH) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking. Which has better earnings & valuation, TBPH or HRMY? Harmony Biosciences has higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$64.38M6.59-$55.19M-$1.15-7.46Harmony Biosciences$714.73M2.25$128.85M$2.5111.18 Does the media refer more to TBPH or HRMY? In the previous week, Harmony Biosciences had 11 more articles in the media than Theravance Biopharma. MarketBeat recorded 13 mentions for Harmony Biosciences and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.23 beat Harmony Biosciences' score of 1.18 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is TBPH or HRMY more profitable? Harmony Biosciences has a net margin of 17.98% compared to Theravance Biopharma's net margin of -78.18%. Harmony Biosciences' return on equity of 23.16% beat Theravance Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma-78.18% -24.79% -13.43% Harmony Biosciences 17.98%23.16%14.24% Does the MarketBeat Community believe in TBPH or HRMY? Theravance Biopharma received 276 more outperform votes than Harmony Biosciences when rated by MarketBeat users. However, 70.97% of users gave Harmony Biosciences an outperform vote while only 62.87% of users gave Theravance Biopharma an outperform vote. CompanyUnderperformOutperformTheravance BiopharmaOutperform Votes34262.87% Underperform Votes20237.13% Harmony BiosciencesOutperform Votes6670.97% Underperform Votes2729.03% Do analysts rate TBPH or HRMY? Theravance Biopharma presently has a consensus price target of $11.33, suggesting a potential upside of 32.17%. Harmony Biosciences has a consensus price target of $53.33, suggesting a potential upside of 90.01%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of TBPH or HRMY? 99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, TBPH or HRMY? Theravance Biopharma has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. SummaryHarmony Biosciences beats Theravance Biopharma on 14 of the 18 factors compared between the two stocks. Remove Ads Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$424.21M$6.34B$5.34B$7.60BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-8.496.8321.7617.83Price / Sales6.59222.48378.0693.28Price / CashN/A65.6738.1534.64Price / Book2.005.836.414.00Net Income-$55.19M$141.86M$3.20B$247.23M7 Day Performance3.06%9.28%6.59%7.42%1 Month Performance-7.10%-12.40%-8.57%-6.15%1 Year Performance-13.56%-12.11%10.11%-0.03% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma1.8982 of 5 stars$8.63-1.1%$11.33+31.3%-9.2%$426.94M$64.38M-8.54359Positive NewsHRMYHarmony Biosciences4.5911 of 5 stars$28.40-2.9%$53.33+87.8%+0.1%$1.63B$714.73M13.46200Short Interest ↓Positive NewsDVAXDynavax Technologies4.3739 of 5 stars$12.49-1.3%$21.50+72.1%-3.4%$1.55B$277.25M69.39350Positive NewsGap DownGLPGGalapagos0.7929 of 5 stars$23.04-3.0%$25.33+10.0%-20.0%$1.52B$275.65M0.001,123News CoverageHigh Trading VolumeCNTACentessa Pharmaceuticals2.9236 of 5 stars$11.28-3.4%$27.71+145.7%+5.5%$1.50B$6.85M-7.37200Gap DownHigh Trading VolumeAGIOAgios Pharmaceuticals3.772 of 5 stars$25.90+0.5%$56.57+118.4%-6.7%$1.48B$36.50M2.28390Analyst RevisionNews CoverageKNSAKiniksa Pharmaceuticals2.6221 of 5 stars$20.28-0.4%$37.17+83.3%+19.7%$1.47B$423.24M-144.85220Upcoming EarningsNews CoveragePositive NewsGap DownHigh Trading VolumeANIPANI Pharmaceuticals3.6037 of 5 stars$66.99-0.8%$79.75+19.0%+2.8%$1.46B$614.38M-121.80600Gap DownHigh Trading VolumeJANXJanux Therapeutics2.697 of 5 stars$24.38-5.4%$92.44+279.2%-45.0%$1.44B$10.59M-20.8430Positive NewsHigh Trading VolumeMNKDMannKind2.2584 of 5 stars$4.69-1.1%$9.21+96.5%+11.6%$1.43B$285.50M67.00400Positive NewsGap DownARWRArrowhead Pharmaceuticals3.4064 of 5 stars$10.25-4.0%$41.44+304.3%-50.0%$1.41B$2.50M-1.98400News Coverage Remove Ads Related Companies and Tools Related Companies HRMY Alternatives DVAX Alternatives GLPG Alternatives CNTA Alternatives AGIO Alternatives KNSA Alternatives ANIP Alternatives JANX Alternatives MNKD Alternatives ARWR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TBPH Stock Free TBPH Stock Alerts